The Readout Loud

350 Folgen

1. 308: An ASCO preview & another Duchenne trial failure

   Vom: 30.5.2024
2. 307: More tumult at BIO & coercive care for sickle cell patients

   Vom: 23.5.2024
3. 306: Live! From the STAT Breakthrough Summit West

   Vom: 16.5.2024
4. 305: Everything you need to know about H5N1 bird flu

   Vom: 9.5.2024
5. 304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

   Vom: 2.5.2024
6. 303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

   Vom: 18.4.2024
7. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

   Vom: 11.4.2024
8. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

   Vom: 4.4.2024
9. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

   Vom: 28.3.2024
10. 299: Live! From the STAT Breakthrough Summit East

    Vom: 21.3.2024
11. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    Vom: 14.3.2024
12. 297: VC turmoil, GLP-1 competition, & the war on recovery

    Vom: 7.3.2024
13. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

    Vom: 29.2.2024
14. 295: Humira’s legacy, CEO symbolism, and genomic surgery

    Vom: 22.2.2024
15. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    Vom: 15.2.2024
16. 293: AI in medicine, detangling hype, and Icelandic DNA

    Vom: 8.2.2024
17. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

    Vom: 1.2.2024
18. 291: The plight of the VC, Gilead's latest setback, & more M&A

    Vom: 25.1.2024
19. 290: Biotech layoffs, slumping stocks, and a 2024 preview

    Vom: 18.1.2024
20. 289: Live! From #JPM24

    Vom: 11.1.2024